Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) kicked off on Tuesday, up 8.58% from the previous trading day, before settling in for the closing price of $15.04. Over the past 52 weeks, CNTA has traded in a range of $7.75-$19.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 2.97%. With a float of $79.75 million, this company’s outstanding shares have now reached $131.66 million.
Let’s determine the extent of company efficiency that accounts for 76 employees. In terms of profitability, gross margin is 89.52%, operating margin of -2342.65%, and the pretax margin is -2294.59%.
Centessa Pharmaceuticals plc ADR (CNTA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Centessa Pharmaceuticals plc ADR is 39.43%, while institutional ownership is 55.19%. The most recent insider transaction that took place on Feb 25 ’25, was worth 175,270. In this transaction Chief Business Officer of this company sold 11,494 shares at a rate of $15.25, taking the stock ownership to the 134,021 shares. Before that another transaction happened on Feb 25 ’25, when Company’s Officer proposed sale 11,494 for $15.25, making the entire transaction worth $175,270.
Centessa Pharmaceuticals plc ADR (CNTA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.97% per share during the next fiscal year.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Take a look at Centessa Pharmaceuticals plc ADR’s (CNTA) current performance indicators. Last quarter, stock had a quick ratio of 21.52. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 311.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Looking closely at Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA), its last 5-days average volume was 0.96 million, which is a jump from its year-to-date volume of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 39.86%. Additionally, its Average True Range was 1.22.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 40.65%, which indicates a significant decrease from 43.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.97% in the past 14 days, which was higher than the 56.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.57, while its 200-day Moving Average is $13.97. However, in the short run, Centessa Pharmaceuticals plc ADR’s stock first resistance to watch stands at $16.88. Second resistance stands at $17.43. The third major resistance level sits at $18.42. If the price goes on to break the first support level at $15.34, it is likely to go to the next support level at $14.35. Now, if the price goes above the second support level, the third support stands at $13.80.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
The company with the Market Capitalisation of 2.15 billion has total of 131,845K Shares Outstanding. Its annual sales at the moment are 6,850 K in contrast with the sum of -151,090 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -42,570 K.
